FR2934492B1 - Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer. - Google Patents

Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.

Info

Publication number
FR2934492B1
FR2934492B1 FR0855304A FR0855304A FR2934492B1 FR 2934492 B1 FR2934492 B1 FR 2934492B1 FR 0855304 A FR0855304 A FR 0855304A FR 0855304 A FR0855304 A FR 0855304A FR 2934492 B1 FR2934492 B1 FR 2934492B1
Authority
FR
France
Prior art keywords
tlr3
apoptosis
ligand
cancer
association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0855304A
Other languages
English (en)
Other versions
FR2934492A1 (fr
Inventor
Serge Lebecque
Charles Dumontet
Yves Pacheco
Lafrasse Claire Rodriguez
Florent Toscano
Yann Estornes
Francois Virard
Invernizzi Isabelle Coste
Toufic Renno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Claude Bernard Lyon 1 UCBL
Hospices Civils de Lyon HCL
Original Assignee
Universite Claude Bernard Lyon 1 UCBL
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Claude Bernard Lyon 1 UCBL, Hospices Civils de Lyon HCL filed Critical Universite Claude Bernard Lyon 1 UCBL
Priority to FR0855304A priority Critical patent/FR2934492B1/fr
Priority to PCT/FR2009/051543 priority patent/WO2010012965A2/fr
Priority to US13/056,341 priority patent/US20120045523A1/en
Publication of FR2934492A1 publication Critical patent/FR2934492A1/fr
Application granted granted Critical
Publication of FR2934492B1 publication Critical patent/FR2934492B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0855304A 2008-07-31 2008-07-31 Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer. Active FR2934492B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0855304A FR2934492B1 (fr) 2008-07-31 2008-07-31 Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.
PCT/FR2009/051543 WO2010012965A2 (fr) 2008-07-31 2009-07-31 Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer
US13/056,341 US20120045523A1 (en) 2008-07-31 2009-07-31 Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic "apoptosis" pathway in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0855304A FR2934492B1 (fr) 2008-07-31 2008-07-31 Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.

Publications (2)

Publication Number Publication Date
FR2934492A1 FR2934492A1 (fr) 2010-02-05
FR2934492B1 true FR2934492B1 (fr) 2012-08-17

Family

ID=40380019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0855304A Active FR2934492B1 (fr) 2008-07-31 2008-07-31 Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.

Country Status (3)

Country Link
US (1) US20120045523A1 (fr)
FR (1) FR2934492B1 (fr)
WO (1) WO2010012965A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
EP2708236A1 (fr) 2012-09-12 2014-03-19 Medizinische Universität Wien Traitement de tumeurs
CA3213217A1 (fr) 2021-04-28 2022-11-03 Raphael Darteil Potentialisation forte d'effets d'agonistes de tlr3 a l'aide d'agonistes de fxr en tant que traitement combine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5131927B2 (ja) * 2006-06-16 2013-01-30 大正製薬株式会社 Ｒｐｎ２遺伝子発現抑制剤の用途

Also Published As

Publication number Publication date
FR2934492A1 (fr) 2010-02-05
US20120045523A1 (en) 2012-02-23
WO2010012965A3 (fr) 2010-04-15
WO2010012965A2 (fr) 2010-02-04

Similar Documents

Publication Publication Date Title
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
ZA200903173B (en) Cancer susceptibility variants on chr8q24.21
CA118542S (en) Shoe
DK2012872T3 (da) Behandling af kræft under anvendelse af elektromagnetiske felter i kombination med kræftlægemidler
EP1985302A4 (fr) Médicament pour le traitement de tumeurs et son utilisation
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
FR2910325B1 (fr) Utilisation de lupulones pour la prevention et la therapie du cancer colorectal.
CA119210S (en) Soap basket
EP1756166A4 (fr) Diagnostic et traitement du cancer de la prostate
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
EP1865954A4 (fr) Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar gamma, telles que le cancer
ZA201000959B (en) The use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases
CL2007003837A1 (es) Uso de compuestos derivados de isosorbide en la prevencion y/o tratamiento de un trastorno intestinal tal como inflamacion intestinal.
FR2934492B1 (fr) Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.
FR2905270B1 (fr) Utilisation de sucres en c7 dans la prevention et le traitement des mycoses
FR2886852B1 (fr) Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DK2107906T3 (da) Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier
IL197509A0 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
BRPI0810682A2 (pt) agente antitumoral em especial para o tratamento de tumores dérmicos, fármaco, kit compreendendo fármaco.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16